Science & Enterprise subscription

Follow us on Twitter

  • Then "Day at the Races" https://t.co/9VT3sNFSZG
    about 14 hours ago
  • The Forward, America’s Leading Jewish News Organization, Goes All Digital. Third-generation subscriber here and wor… https://t.co/2CdgU2WLwR
    about 15 hours ago
  • Our friends at Statista reported on a survey on how the shutdown is affecting people in the U.S., this weekend's in… https://t.co/AbSCYqzGjI
    about 19 hours ago
  • New post on Science and Enterprise: Infographic – Americans Affected by Gov’t Shutdown https://t.co/6uC0lIaMIU #Science #Business
    about 19 hours ago
  • New contributed post on Science and Enterprise: https://t.co/XjQZgoAp3S Hands Off! Robots in Modern Medicine
    about 20 hours ago

Please share Science & Enterprise

RSS
Follow by Email
Facebook
Facebook
Google+
Twitter
Visit Us
LinkedIn
INSTAGRAM

Lilly, Biopharm Partner on Alzheimer’s Treatment in $2B Deal

Neurons illustration

Eli Lilly and Co. is licensing a a treatment candidate for Alzheimer’s disease from biopharmaceutical company AC Immune that aims to block accumulation of tau proteins in the brain. . . . → Read More: Lilly, Biopharm Partner on Alzheimer’s Treatment in $2B Deal

Patent Set for Long-Term Drug Capsules

Star-shaped drug delivery

Techniques for delivering drugs in capsule form that last a week or longer in the patient are expected to receive a patent soon from U.S. authorities. . . . → Read More: Patent Set for Long-Term Drug Capsules

Janssen Licensing Cancer Antibodies in $1.8B Deal

Llama

An affiliate of drug maker Janssen Pharmaceutical is licensing a synthetic antibody to treat blood-related cancers from a developer of antibodies based on the immune system of llamas. . . . → Read More: Janssen Licensing Cancer Antibodies in $1.8B Deal

Gene Silencing Technology Licensed in $3.7B Deal

RNA strand illustration

Dicerna Pharmaceuticals, developing treatments for disease that silence genes by interfering with their RNA instructions, is licensing its technology to drug maker Eli Lilly and Co . . . → Read More: Gene Silencing Technology Licensed in $3.7B Deal

BASF Licensing Precise Crispr Editing from Broad Institute

Crispr-Cas9 illustration

The global chemical company BASF is licensing a more precise form of genome editing from the Broad Institute, a genetics research center affiliated with Harvard University and MIT. . . . → Read More: BASF Licensing Precise Crispr Editing from Broad Institute

Licensing Deal for Bioinks in 3-D Printed Transplant Lungs

Human lungs illustration

A company in Maryland developing alternatives to human organ transplants is licensing a technology to help create 3-D printed lungs for transplantation with bioinks derived from tobacco plants. . . . → Read More: Licensing Deal for Bioinks in 3-D Printed Transplant Lungs

Harvard Spin-Off, AbbVie Partner on Fibrosis Treatments

Handshake

Drug maker AbbVie and biotechnology company Morphic Therapeutic are collaborating on new treatments for fibrosis based on Morphic’s technology blocking proteins that promote fibrosis. . . . → Read More: Harvard Spin-Off, AbbVie Partner on Fibrosis Treatments

Model Biotech Materials Sharing Agreement Unveiled

Lab jars and beakers

A document with standard legal language for terms and conditions of sharing biotechnology materials is now available for academic and industry research labs. . . . → Read More: Model Biotech Materials Sharing Agreement Unveiled

Start-Up Developing Immunometabolism Therapies, Gains $30M Funding

T-cells illustration

A start-up enterprise founded by medical researchers in the U.S. and Europe is developing treatments for cancer and autoimmune disorders that change chemical reactions in immune system cells. . . . → Read More: Start-Up Developing Immunometabolism Therapies, Gains $30M Funding

Biotech in $3.7B Licensing Deal for Hepatitis-B

Hepatitis-B virus

A biotechnology company developing therapies that silence the actions of disease-causing genes is licensing its treatment program for hepatitis-B to Janssen Pharmaceuticals. . . . → Read More: Biotech in $3.7B Licensing Deal for Hepatitis-B